No Data
No Data
Shu Taishen (300204.SZ): Net loss of 3.7694 million yuan in the first quarter
Gelonghui, April 24 | Shu Taishen (300204.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 94.9834 million yuan, an increase of 46.09% over the previous year; net profit attributable to shareholders of listed companies - 37.694 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 4,4392 million yuan; basic earnings per share - 0.01 yuan.
“Doesn't your heart hurt?” Senior shareholders' souls torture Chairman Shu Taishen, and there is no solution to the slump in stock prices|Direct hit on performance
① At the results meeting, investors were most concerned about the company's losses over the years, high R&D expenses, and tight cash flow; ② Currently, the company is facing various operating difficulties. During this period, the souls of self-proclaimed senior shareholders also tortured the company's chairman Zhou Zhiwen, “Doesn't it hurt?”
Shu Taishen (300204.SZ): The company holds Shu Weixin's production approval. Currently, this product is a reserve project
Gelonghui, April 17 | Shu Taishen (300204.SZ) said at an investor relations event that the company holds Shu Weixin's production approval. Currently, this product is the company's reserve project, and the production plan will be adjusted in due course according to market conditions.
Sultaishen (300204.SZ): STSP-0902 injection for clinical trial application for the treatment of oligospermia was accepted
Shu Taishen (300204.SZ) announced that the company received the “Notice of Acceptance”, an administrative license document from the State Drug Administration, and the State Drug Administration agreed to accept the clinical trial application submitted by Shu Taishen for the treatment of STSP-0902 injection for the treatment of oligospermia.
Shu Taishen: STSP-0902 Eye Drops Application for New Drug Clinical Trials Accepted
Shu Taishen announced that STSP-0902 eye drops were accepted for clinical trial applications for new drugs.
Is the expansion of losses compounded by the cutting of multiple pipelines under development, and Shu Taishen's cash flow problem “always difficult”? |Annual Report Interpretation
① After 3 consecutive years of losses, Shu Taishen's loss margin in 2023 increased further. ② Due to the parallel development of multiple R&D pipelines, R&D expenses continued to rise and surpassed annual revenue for the first time, further tightening the company's cash flow. ③ At the same time, the company announced that it will end a number of R&D projects related to COVID-19 indications.
No Data